MDM2 is a central node in the p53 pathway: 12 years and counting.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Cancer Drug Targets

• Publication date

  2005-01-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1568009053332627PMID 15720184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MDM2 and prognosis.

  2004cited by this paper
• Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Dynamics of the p53-Mdm2 feedback loop in individual cells

  2004cited by this paper
• mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation

  2003cited by this paper
• p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.

  2003cited by this paper
• Improving cancer therapy by non-genotoxic activation of p53.

  2003cited by this paper
• Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis

  2003cited by this paper
• BCR/ABL activates mdm2 mRNA translation via the La antigen.

  2003cited by this paper
• The p53-Mdm2 module and the ubiquitin system.

  2003cited by this paper
• p53 Activation by Nitric Oxide Involves Down-regulation of Mdm2*

  2002cited by this paper
• Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents

  2001cited by this paper
• Polyoma virus disrupts ARF signaling to p53

  2001cited by this paper
• Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus

  2001cited by this paper
• The p53 functional circuit.

  2001cited by this paper
• MDM2--master regulator of the p53 tumor suppressor protein.

  2000cited by this paper
• Stress Signals Utilize Multiple Pathways To Stabilize p53

  2000cited by this paper
• An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo

  2000cited by this paper
• Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study.

  2000cited by this paper
• Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.

  2000cited by this paper
• MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis

  2000cited by this paper
• mdm2 mRNA Level is a Prognostic Factor in Soft Tissue Sarcoma

  2000cited by this paper
• Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

  1999cited by this paper
• Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers.

  1999cited by this paper
• P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.

  1999cited by this paper
• Regulation of p53 Function and Stability by Phosphorylation

  1999cited by this paper
• DNA damage‐inducible phosphorylation of p53 at N‐terminal sites including a novel site, Ser20, requires tetramerization

  1999cited by this paper
• MDM2 oncogene as a target for cancer therapy: An antisense approach.

  1999cited by this paper
• Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2

  1999cited by this paper
• Role of two upstream open reading frames in the translational control of oncogene mdm2

  1999cited by this paper
• Low-dose-rate radiation attenuates the response of the tumor suppressor TP53.

  1999cited by this paper
• Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.

  1999cited by this paper
• Nucleolar Arf sequesters Mdm2 and activates p53

  1999cited by this paper
• Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53

  1999cited by this paper
• Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation

  1998cited by this paper
• Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.

  1998cited by this paper
• Differential expression of p53, p21waf1/cip1 and hdm2 dependent on DNA damage in Bloom's syndrome fibroblasts.

  1998cited by this paper
• Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells

  1998cited by this paper
• The MDM2 gene amplification database.

  1998cited by this paper
• Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.

  1997cited by this paper
• DNA damage induces phosphorylation of the amino terminus of p53.

  1997cited by this paper
• A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein

  1997cited by this paper
• Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 Gene

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• Translational regulation of human p53 gene expression.

  1996cited by this paper
• Alterations of the p53, Rb and MDM2 genes in osteosarcoma.

  1996cited by this paper
• Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

  1996cited by this paper
• p53 and MDM2 expression in oral squamous cell carcinoma.

  1996cited by this paper
• Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

  1995cited by this paper
• MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors

  1995cited by this paper
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

  1995cited by this paper
• A functional p53-responsive intronic promoter is contained within the human mdm2 gene.

  1995cited by this paper
• Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.

  1994cited by this paper
• Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.

  1994cited by this paper
• The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.

  1994cited by this paper
• Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.

  1994cited by this paper
• p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

  1993cited by this paper
• Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

  1993cited by this paper
• mdm2 expression is induced by wild type p53 activity.

  1993cited by this paper
• The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.

  1993cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• The human MDM-2 oncogene is overexpressed in leukemias.

  1993cited by this paper
• Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals.

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper
• Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

  1990cited by this paper
• Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line

  1987cited by this paper
• Overproduction of p53 antigen makes established cells highly tumorigenic

  1985cited by this paper
• T antigen is bound to a host protein in SY40-transformed cells

  1979cited by this paper
• Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

  1979cited by this paper

• Cell cycle disorders in podocytes: an emerging and increasingly recognized phenomenon

  2025cites this paper
• Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia

  2024cites this paper
• Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia.

  2024cites this paper
• Garcinol: A novel and potent inhibitor of hyaluronidase enzyme.

  2024cites this paper
• Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review

  2024cites this paper
• Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells.

  2024cites this paper
• Dihydropyrimidine derivatives as MDM2 inhibitors

  2023cites this paper
• Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold.

  2023cites this paper
• LncRNA NRON promotes tumorigenesis by enhancing MDM2 activity toward tumor suppressor substrates

  2023cites this paper
• DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2-p53 Inhibitor.

  2023cites this paper
• Recent advancements in fusion protein technologies in oncotherapy: A review.

  2023cites this paper
• Targeting MDM2 for the development of a new cancer therapy: progress and challenges

  2023cites this paper
• Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.

  2022cites this paper
• Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women

  2022cites this paper
• The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer

  2022cites this paper
• Recent applications of covalent chemistries in protein-protein interaction inhibitors.

  2022cites this paper
• Downregulation of MDM2 by small interference RNA induces apoptosis and sensitizes MCF‐7 breast cells to resveratrol

  2022cites this paper
• Identification and functional interpretation of miRNAs affected by rare CNVs in CAKUT

  2022cites this paper
• Therapeutic Strategies to Activate p53

  2022cites this paper
• Application of In Silico Filtering and Isothermal Titration Calorimetry for the Discovery of Small Molecule Inhibitors of MDM2

  2022cites this paper
• Computational-Model-Based Biopharmaceutics for p53 Pathway Using Modern Control Techniques for Cancer Treatment

  2022cites this paper
• Effect of pharmacodynamical interaction between nutlin-3a and aspirin in the activation of p53.

  2021cites this paper
• Robust p53 Recovery Using Chattering Free Sliding Mode Control and a Gain-Scheduled Modified Utkin Observer.

  2021cites this paper
• Overexpressed tumor protein p53 and the impaired function in aggressively growing calcifying odontogenic cyst: a case report

  2021cites this paper
• Oncogenic WIP1 phosphatase attenuates the DNA damage response and sensitizes p53 mutant Jurkat cells to apoptosis

  2021cites this paper
• Association of Murine Double Minute 2 polymorphisms with gastric cancer: A systematic review with meta-analysis.

  2021cites this paper
• High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice

  2021cites this paper
• Genetic Polymorphism and Their Role in Lung Cancer

  2021cites this paper
• The Role of Ageing and Parenchymal Senescence on Macrophage Function and Fibrosis

  2021cites this paper
• Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses

  2021cites this paper
• Ubiquitin-specific protease 7 mediates platelet-derived growth factor-induced pulmonary arterial smooth muscle cells proliferation

  2021cites this paper
• Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.

  2020cites this paper
• Sex differences in cancer mechanisms

  2020cites this paper
• Computational Investigation on the p53–MDM2 Interaction Using the Potential of Mean Force Study

  2020cites this paper
• Association of MDM2 T309G (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population

  2020cites this paper
• DNA Computing

  2020cites this paper
• Thermal Bioprinting Causes Ample Alterations of Expression of LUCAT1, IL6, CCL26, and NRN1L Genes and Massive Phosphorylation of Critical Oncogenic Drug Resistance Pathways in Breast Cancer Cells

  2020cites this paper
• Rational modulator design by exploitation of protein-protein complex structures.

  2019cites this paper
• Common genetic variants in the TP53 pathway and their impact on cancer

  2019cites this paper
• Akt Regulation of Mdm2-p53 Signaling in Cellular Stress Responses and Tumorigenesis

  2019cites this paper
• Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer

  2019cites this paper
• Mechanistic insights into environmental and genetic risk factors for systemic lupus erythematosus.

  2019cites this paper
• Acute alcohol consumption-induced let-7a inhibition exacerbates hepatic apoptosis by regulating Rb1 in mice.

  2019cites this paper
• A study of the role of microRNAs in gastric cancer : the effect of miR-140-5p dysregulation in the expression of MDM2 in p53-dependent gastric cancer subtypes

  2019cites this paper
• CD4+-Zelldepletion durch MDM2-Deletion vermindert bei Mäusen die Nierenschädigung in der akuten und in der späten Phase der nephrotoxischen Serum-Nephritis

  2019cites this paper
• Design and Synthesis of New Substituted Spirooxindoles as Potential Inhibitors of the MDM 2 − p 53 Interaction

  2019cites this paper
• Sliding mode controller–observer pair for p53 pathway

  2019cites this paper
• Targeting transcription factors in cancer — from undruggable to reality

  2019cites this paper
• Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2-p53 interaction.

  2019cites this paper
• The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.

  2019cites this paper
• Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents.

  2019cites this paper
• MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)

  2019cites this paper
• Targeting transcription factors in cancer — from undruggable to reality

  2019cites this paper
• Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

  2019cites this paper
• MicroRNA-188-3p is involved in sevoflurane anesthesia-induced neuroapoptosis by targeting MDM2

  2018cites this paper
• Effects of mycoplasma infection on the host organism response via p53/NF‐κB signaling

  2018cites this paper
• Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.

  2018cites this paper
• TP53 in adult acute lymphoblastic leukemia

  2018cites this paper
• Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors

  2018cites this paper
• GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development

  2018cites this paper
• Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors

  2018cites this paper
• System‐based strategies for p53 recovery

  2018cites this paper
• A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma

  2018cites this paper
• РОЛЬ МИКОПЛАЗМЕННОЙ ИНФЕКЦИИ В ХРОНИЧЕСКОМ ВОСПАЛЕНИИ И КАНЦЕРОГЕНЕЗЕ, "Цитология"

  2018cites this paper
• MDM 2p 53 Interactions in Human Hepatocellular Carcinoma : What Is the Role of Nutlins and New Therapeutic Options ?

  2018cites this paper
• MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?

  2018cites this paper
• Alterations in expression levels of genes in p53-related pathways determined using RNA-Seq analysis in patients with breast cancer following CIK therapy.

  2017cites this paper
• Interacting partners of FEN1 and its role in the development of anticancer therapeutics

  2017cites this paper
• Partielle Charakterisierung der neuartigen humanen Polyomaviren HPyV9 und HPyV12

  2017cites this paper
• A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.

  2017cites this paper
• Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.

  2017cites this paper
• Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

  2017cites this paper
• MDM2 is implicated in high‐glucose‐induced podocyte mitotic catastrophe via Notch1 signalling

  2017cites this paper
• Molecular basis for prostate cancer racial disparities.

  2017cites this paper
• appendIX 1 assoCIatIon of the GermlIne MDM2 snp309 and TP53 r72p varIants WIth breast CanCer survival in sPeciFic tumor subgrouPs

  2017cites this paper
• On p53 revival using system oriented drug dosage design.

  2017cites this paper
• 128517_Karolina Boman

  2017cites this paper
• Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer.

  2017cites this paper
• Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

  2017cites this paper
• Targeting the MDM 2 – p 53 Protein – Protein Interaction for New Cancer Therapy : Progress and Challenges

  2017cites this paper
• A valuable pair - candidate biomarkers RBM3 and PODXL in urothelial bladder cancer

  2017cites this paper
• AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex

  2017cites this paper
• Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma

  2016cites this paper
• Targeting Notch degradation system provides promise for breast cancer therapeutics.

  2016cites this paper
• Role of the Mdm2 SNIP 309 Polymorphism in Gastric Mucosal Morphologic Patterns of Patients with Helicobacter pylori Associated Gastritis.

  2016cites this paper
• Primary Ewing's Sarcoma/Primitive Neuroectodermal Tumor of Kidney with Caval Involvement in a Pregnant Woman

  2016cites this paper
• HPV Infection in Cervical and other Cancers

  2016cites this paper
• Evaluation of TP53 Pro72Arg and MDM2 SNP285–SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations

  2016cites this paper
• Chapter Nine - Cellular Roles of Beta-Arrestins as Substrates and Adaptors of Ubiquitination and Deubiquitination.

  2016cites this paper
• Prognostic and Predictive Factors in Bladder Cancer

  2016cites this paper
• Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.

  2016cites this paper
• Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis

  2016cites this paper
• Polymorphism of P53-Ets/AP1 transactivation region of MDM2 oncogene and its immunohistochemical analysis in canine tumours.

  2016cites this paper
• Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex

  2016cites this paper
• DNA Based Computers : Molecular Programming and Perspectives

  2016cites this paper
• MDM2 prevents spontaneous tubular epithelial cell death and acute kidney injury

  2016cites this paper
• Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

  2016cites this paper
• LIF is a new p53 negative regulator.

  2015cites this paper
• Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.

  2015cites this paper
• Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.

  2015cites this paper